tradingkey.logo
tradingkey.logo
Suchen

ANI Pharmaceuticals Inc

ANIP
Zur Watchlist hinzufügen
73.590USD
+1.480+2.05%
Handelsschluss 09-16 16:00ET
1.69BMarktkapitalisierung
17.89KGV TTM

mehr Informationen über ANI Pharmaceuticals Inc Unternehmen

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc Profil

BörsenkürzelANIP
Name des UnternehmensANI Pharmaceuticals Inc
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)
Anzahl der mitarbeiter897
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse210 Main Street West
StadtBAUDETTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl56623
Telefon12186343500
Websitehttps://www.anipharmaceuticals.com/
BörsenkürzelANIP
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)

Führungskräfte von ANI Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.87K
-2.35%
Mr. Muthusamy (Samy) Shanmugam
Mr. Muthusamy (Samy) Shanmugam
Head - Research and Development, Chief Operating Officer - New Jersey Operations
Head - Research and Development, Chief Operating Officer - New Jersey Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
55.25K
-5.72%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
229.87K
-2.35%
Mr. Muthusamy (Samy) Shanmugam
Mr. Muthusamy (Samy) Shanmugam
Head - Research and Development, Chief Operating Officer - New Jersey Operations
Head - Research and Development, Chief Operating Officer - New Jersey Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
55.25K
-5.72%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.88K
-5.14%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ANI Pharmaceuticals Inc?

Die fünf größten Anteilseigner von ANI Pharmaceuticals Inc sind: Mr. Chad Gassert

Wie viele Institutionen halten Anteile an ANI Pharmaceuticals Inc (ANIP)?

Mit Stand vom 2026Q1 halten 555 Institutionen Anteile an ANI Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 23.15M, was 101.74% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 57726.00 gestiegen.

Was ist die größte Einnahmequelle von ANI Pharmaceuticals Inc?

Am 2026Q1 erzielte das Geschäft mit Sales of Cortrophin Gel für ANI Pharmaceuticals Inc den höchsten Umsatz in Höhe von 117.13M, was 44.03% des Gesamtumsatzes entspricht.
tradingkey.logo
Risikohinweis: Unsere Website und mobile App bieten lediglich allgemeine Informationen zu bestimmten Anlageprodukten. Finsights stellt keine Finanzberatung oder Empfehlung für ein Anlageprodukt bereit, und die Bereitstellung solcher Informationen darf nicht als Finanzberatung durch Finsights ausgelegt werden.
Anlageprodukte unterliegen erheblichen Anlagerisiken, einschließlich des möglichen Verlusts des investierten Kapitals und sind möglicherweise nicht für jeden geeignet. Die vergangene Wertentwicklung von Anlageprodukten ist nicht unbedingt ein Hinweis auf deren zukünftige Wertentwicklung.
Finsights kann Drittanbietern oder Partnern erlauben, Werbung auf unserer Website oder in unserer mobilen App oder in Teilen davon zu platzieren oder bereitzustellen. Finsights kann für diese Anzeigenvergütung erhalten, basierend auf Ihrer Interaktion mit den Werbeanzeigen.
© Urheberrecht: FINSIGHTS MEDIA PTE. LTD. Alle Rechte vorbehalten.